好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Case of Hepatitis E Transverse Myelitis
Infectious Disease
P4 - Poster Session 4 (5:30 PM-6:30 PM)
4-027
To highlight a rarely reported neurological manifestation of Hepatitis E infection and the importance of keeping this in one's differential diagnosis during the work-up of cord inflammation.
Hepatitis E is a single-stranded, non-enveloped RNA virus contracted through contaminated water or food, formerly considered a travel-associated and self-limiting disease. It has been well established that Hepatitis E can cause neurological complications, including Guillain-Barré syndrome, meningo-encephalitis and neuralgic amyotrophy. It has been rarely described to be associated with a cord syndrome like transverse myelitis.

We report a case of a 38 year old woman with a rapidly progressive weakness (initially affecting the lower limbs) and urine retention following a prodromal viral illness. Her reflexes were brisk. She developed upper limb weakness and a sensory level at T2 as well as respiratory compromise requiring intensive care monitoring and treatment.

Initial MRI brain and cervical spine were reported as normal. CSF analysis revealed an elevated protein. Liver function tests revealed a transaminase rise. Repeat imaging soon after revealed profound abnormalities through the medulla, cervical spine and in particular the thoracic spine, which appeared nodular. An advanced transverse myelitis in the spectrum of acute disseminated encephalomyelitis (ADEM) was diagnosed. A final diagnosis was made based on positive Hepatitis E serology.

Treatment with intravenous immunoglobulin (IVIG), methylprednisolone and plasma exchange resulted in significant improvement of upper limb function, but unfortunately there was no substantial improvement in lower limb or bladder function. This case highlights a rarely reported cause of cord inflammation. Treatment of Hepatitis E is not normally needed in immunocompetent patients, but an important question, and a potential area of future research, is whether antiviral agents like ribavirin, in addition to immunotherapies, would improve outcomes in acute Hepatitis E-associated transverse myelitis.

Authors/Disclosures
Michael Doyle, MRCPI
PRESENTER
No disclosure on file
Thomas S. Monaghan, MD (University Hospital Galway) No disclosure on file